Mediar Therapeutics and Eli Lilly have entered a global licensing agreement to advance MTX-463, a WISP1-neutralizing antibody, into a Phase 2 trial for idiopathic pulmonary fibrosis (IPF).
Mediar Therapeutics has initiated a Phase 1 clinical trial for MTX-463, a first-in-class antibody targeting WISP-1-mediated fibrotic signaling, following FDA clearance. The trial aims to assess the safety, tolerability, and pharmacokinetics of MTX-463 in healthy participants. Additionally, Mediar has formed a Clinical Advisory Board of global fibrosis experts to guide the development of its fibrosis treatment portfolio, including a second antibody program, MTX-474, expected to enter Phase 1 trials in Q3 2024.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.